tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Corcept Therapeutics’ Earnings Call: Growth Amid Challenges
PremiumCompany AnnouncementsCorcept Therapeutics’ Earnings Call: Growth Amid Challenges
1M ago
Corcept Therapeutics price target lowered to $121 from $131 at Piper Sandler
Premium
The Fly
Corcept Therapeutics price target lowered to $121 from $131 at Piper Sandler
1M ago
Corcept Therapeutics price target lowered to $137 from $142 at Canaccord
Premium
The Fly
Corcept Therapeutics price target lowered to $137 from $142 at Canaccord
1M ago
Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome
PremiumCompany AnnouncementsCorcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome
1M ago
Is CORT a Buy, Before Earnings?
Premium
Pre-Earnings
Is CORT a Buy, Before Earnings?
1M ago
Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
Premium
Company Announcements
Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
1M ago
Corcept Therapeutics Completes Key Study on Drug Interaction
PremiumCompany AnnouncementsCorcept Therapeutics Completes Key Study on Drug Interaction
2M ago
Corcept Therapeutics Explores Hypercortisolism in Hypertension: A Market Game Changer?
Premium
Company Announcements
Corcept Therapeutics Explores Hypercortisolism in Hypertension: A Market Game Changer?
2M ago
Corcept Therapeutics’ Phase 2 Study Update: New Hope for Ovarian Cancer Treatment
Premium
Company Announcements
Corcept Therapeutics’ Phase 2 Study Update: New Hope for Ovarian Cancer Treatment
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100